Table 4.
Clinical trials and efficacy of antiresorptive agents.
| Trail(Ref) | Period | Enrolled patients | Design | BMD change | ||
|---|---|---|---|---|---|---|
| Total hip | Lumbar spine | Femoral neck | ||||
| NCT02616744 (82) | 2 years | 171 | Placebo 150mg monthly | -0.19(-10.8%) | -0.09(-5.1%) | |
| Ibandranate 150g monthly | +0.09(+5.3%) | +0.28(+16.6%) | ||||
| Prospective randomized observational study (83) | 24 months | 84 | Anastrozole | -4.8% | -3.5% | |
| Anastrozole plus risedronate | +6.86% | +2.8% | ||||
| NCT00485953 (84) | 24 months | 109 | Oral risedronate 35 mg once weekly | +0.6 | +2.3 | +0.4 |
| Oral placebo 35 mg once weekly | -2.7 | -1.7 | -2.1 | |||